Skip to main content
Neurotherapeutics logoLink to Neurotherapeutics
. 2022 Sep 29;19(5):1686. doi: 10.1007/s13311-022-01286-9

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Michael Benatar 1,, Joanne Wuu 1, Peter M Andersen 2, Robert C Bucelli 3, Jinsy A Andrews 4, Markus Otto 5, Nita A Farahany 6, Elizabeth A Harrington 7, Weiping Chen 8, Adele A Mitchell 8, Toby Ferguson 8, Sheena Chew 8, Liz Gedney 8, Sue Oakley 8, Jeong Heo 8, Sowmya Chary 8, Laura Fanning 8, Danielle Graham 8, Peng Sun 8, Yingying Liu 8, Janice Wong 8, Stephanie Fradette 8,
PMCID: PMC9606151  PMID: 36175782

Correction to: Neurotherapeutics https://doi.org/10.1007/s13311-022-01237-4

Due to an error during production, captions for Fig. 1, Fig. 5 and Fig. 6 in this article were formatted in a confusing manner in this article as originally published.

The original article has been corrected.

Footnotes

Jeong Heo was affiliated with Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA at the time the study was designed.

Janice Wong was affiliated with Biogen, 225 Binney Street, Cambridge, MA 02142, USA at the time the study was designed.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Michael Benatar, Email: mbenatar@med.miami.edu.

Stephanie Fradette, Email: Stephanie.fradette@biogen.com.


Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES